STOCK TITAN
  1. Home
  2. News
  3. CSTL

Castle Biosciences, Inc. - CSTL STOCK NEWS

Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.

Castle Biosciences, Inc. (symbol: CSTL) is a pioneering company specializing in diagnostic tests for a variety of cancers. Founded in 2008, Castle Biosciences has dedicated itself to advancing cancer care through objective and accurate testing. The company's primary mission is to provide physicians and patients with personalized, clinically actionable genomic information to facilitate more precise treatment decisions.

Castle Biosciences offers a range of diagnostic tests that assist doctors in the treatment of various cancers. Their current product portfolio includes tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma. Notably, their products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, all designed to provide vital information that can influence the course of cancer treatment.

The company is not just limited to its existing portfolio; it actively engages in research programs aimed at developing diagnostic tests for other under-served cancers, such as rectal cancer and soft tissue sarcoma. These initiatives underscore Castle Biosciences' commitment to addressing gaps in cancer diagnostics and improving patient outcomes.

Castle Biosciences collaborates closely with leading members of the oncology community to ensure that their tests are both innovative and clinically relevant. This collaboration spans the discovery, development, and practical utilization of their diagnostic tests, reinforcing their standing as a crucial player in the field of cancer diagnostics.

The company is currently in a robust financial condition, reflecting its successful commercialization efforts and consistent revenue growth. Recent achievements include expanding their test portfolio and forging strategic partnerships aimed at broadening their market reach and enhancing their technological capabilities.

For the latest updates and detailed information on Castle Biosciences, Inc. and its products, please visit their official website at www.castlebiosciences.com.

News

Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announced study results demonstrating the superior risk stratification of DecisionDx-Melanoma in stage I melanoma patients. The study, including 5,651 patients, showed better outcomes than AJCC8 staging. Incorporating DecisionDx-Melanoma may enhance clinical decision-making for more precise information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
none
-
News

Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024

Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) will release its financial results for the fourth quarter and year ended Dec. 31, 2023, after the close of market on Wednesday, Feb. 28, 2024. The company will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Access details for the webcast and phone conference call are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
earnings
-
News

New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announced a study in The Journal of Clinical and Aesthetic Dermatology which found that using its DecisionDx-SCC test to guide adjuvant radiation therapy (ART) decisions for patients with squamous cell carcinoma (SCC) could result in substantial Medicare healthcare savings of up to approximately $972 million annually. The study also highlighted the potential to improve patient care by providing added confidence in decisions to forgo radiation therapy when a patient’s risk of metastasis is low.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
News

Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®

Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) will present new data on its dermatologic gene expression profile (GEP) tests at the 2024 Winter Clinical Dermatology Conference. The data includes real-world evidence confirming risk stratification for melanoma, identifying high-risk SCC patients, diagnostic discordance for melanocytic lesions, and gene expression differences in skin samples of inflammatory skin diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announced that its COO, Kristen Oelschlager, has been named to The Healthcare Technology Report’s Top 25 Women Leaders in Biotechnology of 2023. Oelschlager's extensive background and instrumental role in Castle's success have led to her recognition as a driving force in biotechnology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags
none
-
News

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results

Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) expects to deliver total revenue of over $210 million in 2023, representing at least 53% growth over 2022. The company also anticipates cash, cash equivalents, and marketable investment securities to be approximately $243 million by the end of 2023. The preliminary, unaudited results for the fourth quarter and full year ended Dec. 31, 2023, show significant growth in test reports delivered, indicating a successful year for Castle Biosciences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
earnings
News

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) granted restricted stock units to 52 employees covering 170,913 shares of common stock as an inducement material to their entering into employment. The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting annually thereafter in three equal installments, subject to the employee’s continued service through each applicable vesting date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
none
-
News

Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) published a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that revealed 82.4% of NPs/PAs using DecisionDx-Melanoma in clinical practice would change patient treatment plans based on high-risk test results in thin melanoma tumors. Similarly, 81.3% would alter treatment plans for Stage 1 tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
-
News

Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting

Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) presented robust data at the 2023 ASDS Annual Meeting, reinforcing the clinical validity and utility of its skin cancer test portfolio. The data highlighted the DecisionDx-Melanoma and DecisionDx-SCC tests, demonstrating their ability to predict tumor recurrence in stage I cutaneous melanoma and identify patients at less than 5% risk of sentinel lymph node biopsy metastasis. The DecisionDx-SCC test was also shown to reduce healthcare costs and improve metastatic risk assessment for cutaneous squamous cell carcinoma patients. MyPath Melanoma testing was presented as a valuable tool in the diagnostic work-up of ambiguous melanocytic neoplasms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.01%
Tags
none
News

Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) Earns National Recognition and Three Top Workplaces Culture Excellence Awards
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
none

FAQ

What is the current stock price of Castle Biosciences (CSTL)?

The current stock price of Castle Biosciences (CSTL) is $28.88 as of November 21, 2024.

What is the market cap of Castle Biosciences (CSTL)?

The market cap of Castle Biosciences (CSTL) is approximately 819.2M.

What does Castle Biosciences specialize in?

Castle Biosciences specializes in diagnostic tests for various cancers, providing genomic information to aid in treatment decisions.

When was Castle Biosciences founded?

Castle Biosciences was founded in 2008.

What types of cancer does Castle Biosciences have tests for?

Castle Biosciences has tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma.

What are some of Castle Biosciences' notable products?

Notable products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME.

Is Castle Biosciences involved in research for new diagnostic tests?

Yes, they have active research programs in rectal cancer and soft tissue sarcoma, among others.

Where can I find more information about Castle Biosciences and its products?

You can visit their official website at www.castlebiosciences.com for more detailed information.

What is the primary mission of Castle Biosciences?

The primary mission is to provide personalized, clinically actionable genomic information to make more accurate treatment decisions.

Does Castle Biosciences collaborate with other entities?

Yes, they work closely with outstanding members of the oncology community throughout the discovery, development, and utilization of their tests.

What is Castle Biosciences' financial condition?

The company is in a robust financial condition, reflecting successful commercialization efforts and consistent revenue growth.

How does Castle Biosciences contribute to cancer care?

By providing objective and accurate diagnostic tests, Castle Biosciences helps advance cancer care and improve patient outcomes.

Stock CSTL logo
Castle Biosciences, Inc.

Nasdaq:CSTL

CSTL Rankings

#2710 Ranked by Market Cap
N/A Ranked by Dividends

CSTL Stock Data

819.21M
27.11M
3.25%
95.3%
5.74%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
FRIENDSWOOD